Decreased Efficacy of Sofosbuvir/Velpatasvir in HIV Patients Coinfected with HCV Genotype 3b

References

• Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet7(5), 396–415 (2022).
   Web of Science ®Google Scholar
• Calvaruso V , CraxìA. Hepatic benefits of HCV cure. J. Hepatol.73(6), 1548–1556 (2020).
   PubMed Web of Science ®Google Scholar
• Rinaldi L , NevolaR , FranciGet al. Risk of hepatocellular carcinoma after HCV clearance by direct-acting antivirals treatment predictive factors and role of epigenetics. Cancers12(6), 1351 (2020).
   PubMed Web of Science ®Google Scholar
• Shah R , AhovegbeL , NiebelM , ShepherdJ , ThomsonEC. Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. J. Hepatol.75(2), 462–473 (2021).
   PubMed Web of Science ®Google Scholar
• Gupta N , MbituyumuremyiA , KabahiziJet al. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. Lancet4(2), 119–126 (2019).
   Web of Science ®Google Scholar
• Zarębska-Michaluk D . Genotype 3-hepatitis C virus’ last line of defense. World J. Gastroenterol.27(11), 1006–1021 (2021).
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver . EASL recommendations on treatment of hepatitis C: final update of the series. J. Hepatol.73(5), 1170–1218 (2020).
   PubMed Web of Science ®Google Scholar
• Wu N , RaoHY , YangWBet al. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chin. Med. J.133(3), 253–261 (2020).
   PubMed Web of Science ®Google Scholar
• Gimeno-Ballester V , ButiM , SanMiguel R , RiveiroM , EstebanR. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: a systematic review. J. Viral Hepat.24(11), 904–916 (2017).
   PubMed Web of Science ®Google Scholar
• Khan SI , RezaMM , CroweSMet al. People who inject drugs in Bangladesh - The untold burden! Internat. J. Infect. Dis. 83, 109–115 (2019).
   PubMed Web of Science ®Google Scholar
• Lu J , ZhangL , XuXet al. Hepatitis C virus genotype diversity and distribution among methadone maintenance treatment patients in Jiangsu, China. Drug Alcohol Depend.194, 101–106 (2019).
   PubMed Web of Science ®Google Scholar
• Chen M , MaY , LuoHet al. Analysis on genotypes of hepatitis C virus among intravenous drug users in Kunming, Yunnan. Zhonghua Liu Xing Bing Xue Za Zhi36(9), 994–997 (2015).
   PubMedGoogle Scholar
• Wei L , LimSG , XieQet al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase III trial. Lancet4(2), 127–134 (2019).
   Web of Science ®Google Scholar
• Huang R , RaoH , JiangD , MoH , BrainardD , WeiL. Comparison of efficacy of Sofosbuvir plus ribavirin in Chinese Patients with genotype 3a or 3b HCV infection. Hepatology68, 400A–401A (2018).
   Web of Science ®Google Scholar
• Wei L , LimSG , XieQet al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase III trial. Lancet4(2), 127–134 (2019).
   Web of Science ®Google Scholar
• Bichoupan K , DieterichDT. Hepatitis C in HIV-infected patients: impact of direct-acting antivirals. Drugs74(9), 951–961 (2014).
   PubMed Web of Science ®Google Scholar
• Wyles DL , SulkowskiMS , DieterichD. Management of hepatitis C/HIV coinfection in the era of highly effective hepatitis C virus direct-acting antiviral therapy. Clin. Infect. Dis.63(Suppl. 1), S3–S11 (2016).
   PubMedGoogle Scholar
• Platt L , EasterbrookP , GowerEet al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet16(7), 797–808 (2016).
   Web of Science ®Google Scholar
• AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention . Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition). Zhonghua nei ke za zhi60(12), 1106–1128 (2021).
   PubMedGoogle Scholar
• Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association Society of Infectious Diseases . Guidelines for the prevention and treatment of hepatitis C (2019 version). Zhonghua gan zang bing za zhi27(12), 962–979 (2019).
   PubMedGoogle Scholar
• Md Z , JaroszewiczJ , KaPet al. Effectiveness and safety of pangenotypic regimens in the most difficult to treat population of genotype 3 HCV infected cirrhotics. J. Clinic. Med.10(15), 3280 (2021).
   PubMed Web of Science ®Google Scholar
• Tao YC , DengR , WangMLet al. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study. Virol. J.15(1), 150 (2018).
   PubMedGoogle Scholar
• Foster GR , AfdhalN , RobertsSKet al. Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection. N England J. Med.373(27), 2608–2617 (2015).
   PubMed Web of Science ®Google Scholar
• Feld JJ , JacobsonIM , HézodeCet al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N England J. Med.373(27), 2599–2607 (2015).
   PubMed Web of Science ®Google Scholar
• Mogalian E , StammLM , OsinusiAet al. Drug–drug interaction studies between hepatitis C virus antivirals sofosbuvir/velpatasvir and boosted and unboosted human immunodeficiency virus antiretroviral regimens in healthy volunteers. Clin. Infect. Dis.67(6), 934–940 (2018).
   PubMed Web of Science ®Google Scholar
• Bruno G , SaracinoA , ScudellerLet al. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Int. J. Infect. Dis. 62, 64–71 (2017).
   PubMed Web of Science ®Google Scholar
• Kim WR , BergT , AsselahTet al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J. Hepatol.64(4), 773–780 (2016).
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado . EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol.63(1), 237–264 (2015).
   PubMed Web of Science ®Google Scholar
• Li Y , LiL , LiuJet al. Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China. Hepatol. Int.12(5), 465–473 (2018).
   PubMed Web of Science ®Google Scholar
• Mangia A , MilliganS , KhaliliMet al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts. Liver Int.40(8), 1841–1852 (2020).
   PubMed Web of Science ®Google Scholar
• Hezode C , ReauN , SvarovskaiaESet al. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J. Hepatol.68(5), 895–903 (2018).
   PubMed Web of Science ®Google Scholar
• Wyles D , BräuN , KottililSet al. Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase III study. Clin. Infect. Dis.65(1), 6–12 (2017).
   PubMed Web of Science ®Google Scholar
• Wang X , WeiL. Direct-acting antiviral regimens for patients with chronic infection of hepatitis C virus genotype 3 in China. J. Clin. Translat. Hepatol.9(3), 419–427 (2021).
   PubMed Web of Science ®Google Scholar
• Gottwein JM , PhamLV , MikkelsenLSet al. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1–7 and Escape Variants. Gastroenterology154(5), 1435–1448 (2018).
   PubMed Web of Science ®Google Scholar
• Nguyen D , SmithD , Vaughan-JacksonA , MagriA , BarnesE , SimmondsP. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. J. Hepatol.73(4), 794–799 (2020).
   PubMed Web of Science ®Google Scholar
• Smith D , MagriA , BonsallDet al. Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology69(5), 1861–1872 (2019).
   PubMed Web of Science ®Google Scholar
• Hu C , YuanG , LiuJet al. Sofosbuvir-based therapies for patients with hepatitis C virus infection: real-world experience in China. Canadian J. Gastroenterol. Hepatol.2018, 3908767 (2018).
   PubMed Web of Science ®Google Scholar
• Mei YY , ChenYM , WuYK , ZhangXH , XuWX. Efficacy and safety of sofosbuvir-based direct-acting antiviral agents treatment for patients with genotype 3/6 hepatitis C virus infection. Canadian J. Gastroenterol. Hepatol.2020, 8872120 (2020).
   PubMed Web of Science ®Google Scholar
• Ji F , LiJ , LiuLet al. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. J. Gastroenterol. Hepatol.36(3), 767–774 (2021).
   PubMed Web of Science ®Google Scholar
• Patel SV , JayaweeraDT , AlthoffKNet al. Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. PLOS ONE15(2), e0228847 (2020).
   PubMed Web of Science ®Google Scholar
• Sarrazin C , IsakovV , SvarovskaiaESet al. Late relapse versus hepatitis C Virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin. Infect. Dis.64(1), 44–52 (2017).
   PubMed Web of Science ®Google Scholar
• Swain MG , LaiMY , ShiffmanMLet al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology139(5), 1593–1601 (2010).
   PubMed Web of Science ®Google Scholar
• Lledó GM , CarrascoI , Benítez-GutiérrezLMet al. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. AIDS32(16), 2347–2352 (2018).
   PubMed Web of Science ®Google Scholar
• Bachofner JA , ValliPV , KrögerAet al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int.37(3), 369–376 (2017).
   PubMed Web of Science ®Google Scholar
• Laguno M , Martínez-RebollarM , CasanovaMet al. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients. Clin. Microbiol. Infect.28(4), 610.e611–610.e617 (2022).
   Web of Science ®Google Scholar
• Kang Q , XuJ , LuoHet al. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication. J. Viral Hepat.28(9), 1284–1292 (2021).
   PubMed Web of Science ®Google Scholar
• Rial-Crestelo D , SepúlvedaMA , González-GascaFJet al. Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents? AIDS 34(3), 427–432 (2020).
   PubMed Web of Science ®Google Scholar
• Apostolova N , Gomez-SucerquiaLJ , GortatA , Blas-GarciaA , EspluguesJV. Autophagy as a rescue mechanism in efavirenz-induced mitochondrial dysfunction: a lesson from hepatic cells. Autophagy7(11), 1402–1404 (2011).
   PubMed Web of Science ®Google Scholar
• Marot A , TrépoE , DoerigC , SchoepferA , MorenoC , DeltenreP. Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding. Liver Int.37(5), 707–716 (2017).
   PubMed Web of Science ®Google Scholar
• Hermans LE , MoorhouseM , CarmonaSet al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. Lancet18(2), 188–197 (2018).
   Web of Science ®Google Scholar
• Liu CH , LeeMH , LinJWet al. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. J. Hepatol.72(5), 839–846 (2020).
   PubMed Web of Science ®Google Scholar
• Ray AS , FordyceMW , HitchcockMJ. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res.125, 63–70 (2016).
   PubMed Web of Science ®Google Scholar